Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


EU Updates Definition Of ‘Similarity’ For Orphans In View Of Advances In Gene And Cell Therapies

Executive Summary

Practical advice has also been issued on how the concept of similarity should be applied to advanced therapy medicinal products.

You may also be interested in...

Orphan Products: US FDA Working On ‘Sameness’ Policy For Cell And Gene Therapies

Industry seeks clarity as to when a subsequent product will be judged the ‘same’ as a previously approved product that holds seven years of blocking exclusivity. CBER Director Marks says agency is working to put its views in writing soon but notes the US and EU may be headed in different directions on the issue.

Changes To EU Orphan Similarity Concept Could Change Innovation Threshold For 10-Year Exclusivity

The European Commission has proposed changes to the existing criteria used for determining whether a new medicinal product is similar to an already authorized orphan drug and, therefore, whether it can be accepted for evaluation and granted 10-year market exclusivity.

EMA Works On Definition To Support Similarity Assessments For Orphan Drugs

The European Medicines Agency is working on a definition for 'principal molecular structural features'- a term in the EU orphan drugs legislation for determining the similarity between a drug in the pre-authorization phase and a drug that has already received orphan designation or market authorization.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts